Pharmaceutical care in the treatment of acute respiratory viral infections: the phytoneering possibilities from the perspective of evidence-based medicine




Іmupret®, phytoneering, acute respiratory viral infections, treatment, prevention


For many years, acute respiratory viral infections and influenza have remained a serious medical and social health problem as a leading cause of missing days at work by adults and schools or kindergartens by children, increased costs of medical care and complications. Therefore, to date, the prevention, treatment and avoidance of complications demand new therapeutic methods based on a systemic scientific approach and aimed at reducing the disease duration, improving the quality of life of the patient and reducing the risks of dangerous consequences. The combined herbal medicine Imupret® created with the unique concept of phytoneering has significant advantages for solving the problem of the common cold and flu. The efficacy and safety of Imupret® has been confirmed by a number of clinical studies that prove its complex effect on the course of acute upper respiratory tract infections, prevention of their recurrence and reduction of the need for antibiotic therapy, which is very important in the context of the worsening global problem of antibiotic resistance. The complex composition of Imupret® provides several pharmacological effects: maintenance of the immune response activity, the anti-inflammatory action and the mucosal edema reduction, the antiviral and antibacterial effect, as well as the detoxifying action. Imupret® has immune rehabilitation properties and increases the resistance of the human body, in particular thanks to normalization of microbiocenosis and the functioning of various immune defense elements, including local factors. The adaptive and immunoregulatory properties of Imupret® provide the immune modulating effect without “traumatic” effects on the immune system and other side effects unlike most synthetic immune stimulators. Imupret® is characterized by high safety of use, particularly in children, the drug reduces the frequency of cold, relieve of the illness and its duration, improves the quality of life of patients. Imupret® is available in the form of tablets and drops for oral use, it allows to choose a rational dosage form taking into account age, occupational characteristics, compliance, ease of administration, psychological factors and individual preferences.

Conclusions. According to the evidence data review, the prescription of Imupret® for the treatment and prevention of complications and relapses of acute respiratory viral infections is rational due to the complex action focused on all links of pathogenesis, namely antiviral, actibacterial, anti-inflammatory, immune modulating effects.

Author Biographies

T. S. Sakharova, National University of Pharmacy of the Ministry of Health of Ukraine

Doctor of Pharmacy (Dr. habil.), professor, head of the Clinical Pharmacology and Clinical Pharmacy Department

N. P. Bezugla, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Medicine (Ph.D.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

I. A. Otrishko, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

K. O. Zupanets, National University of Pharmacy of the Ministry of Health of Ukraine

Doctor of Pharmacy (Dr. habil.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

K. L. Ratushna, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph.D.), teaching assistant of the Department of Clinical Pharmacology and Clinical Pharmacy


The Center for Public Health of the Ministry of Health of Ukraine. (2020). Zakhvoriuvanist na hryp ta HRVI v Ukraini. Available at:

Holubovska, O., Shkurba, V., Pechinka, A. (2012). Zdorovia natsii, 1, 129-140. Available at:

World Health Organization. (2020). Influenza (Seasonal). Available at:

Klinichna nastanova, zasnovana na dokazakh: «Hryp ta hostri respiratorni infektsii»: proekt. (2018). Available at:

Iuliano, A. D., Roguski, K. M., Chang, H. H., Muscatello, D. J., Palekar, R., Tempia, S., Cohen, C., Gran, J. M. et al. (2018). Global Seasonal Influenza-associated Mortality Collaborator Network Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet, 391 (10127), 1285–1300. doi:

European Centre for Disease Prevention and Control. (2020). Regional situation assessment ‑ Seasonal influenza, 2019–2020. Available at:

Centers for Disease Control and Prevention. (n.d). FluView Interactive. Available at:

Allan, G. M., Arroll, B. (2014). Prevention and treatment of the common cold: making sense of the evidence. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, 186 (3), 190–199. doi:

Pro zatverdzhennia Pereliku likarskykh zasobiv, dozvolenykh dlia zastosuvannia v Ukraini, yaki vidpuskaiutsia bez retseptiv z aptek ta yikh strukturnykh pidrozdiliv: nakaz MOZ Ukrainy vid 18.04.2019 r. № 876. (2019). Ofitsiinyi visnyk Ukrainy, 46, 19.

Chernykh, V. P., Zupanets, I. A., Kupnovytska, I. H. (Eds.). (2013). Klinichna farmatsiia. Kharkiv: Zoloti storinky, 912.

Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry hostrykh zapalnykh zakhvoriuvanniakh verkhnikh dykhalnykh shliakhiv ta vukha: nakaz MOZ Ukrainy vid 11.02.2016 №85. (2016). Available at:

Chernykh, V. P., Zupanets, I. A., Lishchyshyna, O. M. (Eds.). (2014). Protokoly provizora (farmatsevta). Kharkiv: Zoloti storinky, 232.

Mokiia-Serbina, S. O., Vasylenko, N. V., Lytvynova, T. V., Shelevytska V. A. (2015). Klinichni rekomendatsii z diahnostyky, likuvannia ta profilaktyky HRVI u ditei rannoho viku. 2nd ed. Kryvyi Rih: R. A. Kozlov, 158.

Kovalenko, V. N. (2019). Kompendium 2018 – lekarstvennye preparaty. Kyiv: Morion, 832.

Nakaz Ministerstva okhorony zdorov’ia Ukrainy vid 06.07 2014 № 499 «Unifikovanyi klinichnyi protokol pervynnoi medychnoi dopomohy doroslym ta ditiam «Hostri respiratorni infektsii». Available at:

Zupanets, I. A. et al. (2018). Farmatsevtychna opika. Kyiv: Farmatsevt Praktyk, 224.

Fashner, J., Ericson, K., Werner, S. (2012). Treatment of the common cold in children and adults. Am Fam Physician, 86 (2), 153‑159.

Zupanets, I. A., Heorhyiants, M. A., Bezuhlaia, N. P., Sakharova, T. S. (2014). Medicine of Ukraine, 5 (6), 5-9.

Recommended use of antivirals. Available at:

Instruktsiia dlia zastosuvannia IMUPRET® krapli. Available at:

Instruktsiia dlia zastosuvannia IMUPRET® tabletky, vkryti obolonkoiu. Available at:

Sait Derzhavnoho reiestru likarskykh zasobiv Ukrainy. Available at:

Zupanets, I. A., Sakharova T. S, Bezuhlaia, N. P. (2014). Medicine of Ukraine, 9 (185), 36-40.

Jur’ev, K. L. (2008). Ukrainian medical Journal, 3 (65), 93–105.

Berger, T. (2009). Sovremennaia pediatriia, 2, 58-63.

Sovremennye podhody k fitoterapii ostryh i hronicheskih zabolevanij verhnih dyhatel’nyh putej : mirovoj nauchnyj opyt. (2012). Sovremennaia pediatriia, 2, 83-87.

Wagner, H. (2000). Expert report. In: Tonsilgon — N Coated Tablets. Part III and IV. File 1. Pharmacological and toxicological documentation and Postmarketing surveillance studies and experience reports. Germany : Bionorica AG, 30.

Berger, T. (2008). Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract. MMW Fortschr Med, 26 (150), Suppl 2, 85-90.

Tsodikova, O. A. (2012). Sovremennaia pediatriia, 4, 122-127.

Drynov, H. I. (2013). Sovremennaia pediatriia, 6 (54), 116-120.

Hospodarskyi, F. Ya., Hospodarska, Kh. O. (2016). Sovremennaia pediatriia, 1, 105-110.

Horbachevskii, P. R., Paramonova, N. S. (2016). Family Medicine, 2 (64), 27-28.

Marushko, Yu. V., Hyshchak, T. V., Lysovets, O. V., Marushko, Ye. Yu. (2015). Child`s health, 1 (60), 49-54.

Popovych, V., Koshel, I., Malofiichuk, A., Pyletska, L., Semeniuk, A., Filippova, O., Orlovska, R. (2019). A randomized, open-label, multicenter, comparative study of therapeutic efficacy, safety and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb in the treatment of acute non-bacterial tonsillitis in children aged 6 to 18 years. American journal of otolaryngology, 40 (2), 265–273. doi:

Popovych, V. I., Koshel, I. V. (2014). Journal of Ear, Nose and Throat Diseases ,6, 57‑68.

Abaturov, A. E., Borisova, T. P. (2016). Sovremennaia pediatriia, 2 (74), 66‑72.

Abaturov, A. E., Ahafonova, E. A. (2015). Zdorovia Ukrainy. Pediatriia, 3 (34), 24-26.

Abaturov, A. E., Kriuchko, T. A. (2018). Child`s health, 5, 438‑443. Available at:

Prohorov, E. V., Tolstikova, A. E., Pedenko, A. V., Burbelo, E. N. (2015). Zdorovia Ukrainy, 3, 88.

Mel’nikov, O. F., Ryl’skaia, O. H., Tsimar, A. V., Peleshenko, N. A. (2013). Medical Nature, 2 (14), 70-74.

Hostanska, K., Melzer, J., Amon, A., Saller, R. (2011). Suppression of interleukin (IL)-8 and human beta defensin-2 secretion in LPS-and/or IL-1β-stimulated airway epithelial A549 cells by a herbal formulation against respiratory infections (BNO 1030). Journal of Ethnopharmacology, 134 (2), 228-233. doi: 10.1016/j.jep.2010.12.006.





Clinical Pharmacology and Pharmacotherapy